Valeant's $47 billion bid to buy eye-drug giant Allergan is far from a done deal, but that isn't stopping Valeant's management team from making big promises to investors about what might happen after the acquisition. While briefing a few of Allergan's largest investors, Valeant's top brass said it would consider splitting up the company if it became too big to support its aggressive M&A strategy, according to <em>Reuters</em>.
written on 19.05.2014
Valeant's $47B Allergan buyout could spawn a breakup, CEO tells investors
